FI106556B - Menetelmä puolisynteettisten glykosaminoglykaanien valmistamiseksi - Google Patents
Menetelmä puolisynteettisten glykosaminoglykaanien valmistamiseksi Download PDFInfo
- Publication number
- FI106556B FI106556B FI931741A FI931741A FI106556B FI 106556 B FI106556 B FI 106556B FI 931741 A FI931741 A FI 931741A FI 931741 A FI931741 A FI 931741A FI 106556 B FI106556 B FI 106556B
- Authority
- FI
- Finland
- Prior art keywords
- water
- nucleophilic
- semi
- heparin
- acid
- Prior art date
Links
- 229920002683 Glycosaminoglycan Polymers 0.000 title claims abstract description 62
- 238000000034 method Methods 0.000 title claims description 16
- 230000008569 process Effects 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title description 3
- 229920000669 heparin Polymers 0.000 claims abstract description 44
- 229960002897 heparin Drugs 0.000 claims abstract description 44
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical group OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 42
- 229920002971 Heparan sulfate Chemical group 0.000 claims abstract description 38
- 239000002253 acid Substances 0.000 claims abstract description 18
- 230000000269 nucleophilic effect Effects 0.000 claims abstract description 10
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- 238000006243 chemical reaction Methods 0.000 claims description 31
- 239000012434 nucleophilic reagent Substances 0.000 claims description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 23
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 16
- 239000007864 aqueous solution Substances 0.000 claims description 15
- 239000011541 reaction mixture Substances 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 11
- 230000007935 neutral effect Effects 0.000 claims description 10
- -1 heterocyclic amines Chemical group 0.000 claims description 8
- 238000000502 dialysis Methods 0.000 claims description 7
- 239000012153 distilled water Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- 239000012298 atmosphere Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000011261 inert gas Substances 0.000 claims description 5
- 150000007530 organic bases Chemical class 0.000 claims description 5
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 239000000539 dimer Substances 0.000 claims description 4
- 125000003700 epoxy group Chemical group 0.000 claims description 4
- 150000007529 inorganic bases Chemical class 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 150000002989 phenols Chemical group 0.000 claims description 4
- 239000002798 polar solvent Substances 0.000 claims description 4
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical group S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 150000001298 alcohols Chemical group 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 150000001340 alkali metals Chemical class 0.000 claims description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 3
- 150000001413 amino acids Chemical group 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 claims description 3
- 108090000765 processed proteins & peptides Chemical group 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 2
- 150000001414 amino alcohols Chemical group 0.000 claims description 2
- 125000005365 aminothiol group Chemical group 0.000 claims description 2
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 150000004662 dithiols Chemical group 0.000 claims description 2
- 150000002429 hydrazines Chemical class 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 150000003335 secondary amines Chemical class 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000012279 sodium borohydride Substances 0.000 claims description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical group CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
- 239000010953 base metal Substances 0.000 claims 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims 1
- 239000000920 calcium hydroxide Substances 0.000 claims 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 claims 1
- 150000002443 hydroxylamines Chemical class 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 239000012312 sodium hydride Substances 0.000 claims 1
- 229910000104 sodium hydride Inorganic materials 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 150000003573 thiols Chemical group 0.000 claims 1
- 230000002785 anti-thrombosis Effects 0.000 abstract description 18
- 208000032843 Hemorrhage Diseases 0.000 abstract description 12
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 230000002429 anti-coagulating effect Effects 0.000 abstract 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 27
- 125000003277 amino group Chemical group 0.000 description 19
- 239000004471 Glycine Substances 0.000 description 13
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- 230000000144 pharmacologic effect Effects 0.000 description 11
- 208000034158 bleeding Diseases 0.000 description 10
- 230000000740 bleeding effect Effects 0.000 description 10
- 230000004580 weight loss Effects 0.000 description 10
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 7
- 125000000600 disaccharide group Chemical group 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000035484 reaction time Effects 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- AEMOLEFTQBMNLQ-VCSGLWQLSA-N alpha-L-iduronic acid Chemical class O[C@@H]1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-VCSGLWQLSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 150000001720 carbohydrates Chemical group 0.000 description 4
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 150000002118 epoxides Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- VRVRGVPWCUEOGV-UHFFFAOYSA-N 2-aminothiophenol Chemical compound NC1=CC=CC=C1S VRVRGVPWCUEOGV-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 108010008488 Glycylglycine Proteins 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 239000004158 L-cystine Substances 0.000 description 2
- 235000019393 L-cystine Nutrition 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229940043257 glycylglycine Drugs 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 230000014508 negative regulation of coagulation Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- ZJLMKPKYJBQJNH-UHFFFAOYSA-N propane-1,3-dithiol Chemical compound SCCCS ZJLMKPKYJBQJNH-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical group S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- CHJFZKBUNXDBEL-UHFFFAOYSA-N 2-[(2-aminoacetyl)amino]ethanesulfonic acid Chemical compound NCC(=O)NCCS(O)(=O)=O CHJFZKBUNXDBEL-UHFFFAOYSA-N 0.000 description 1
- AFLBTVGQCQLOFJ-UHFFFAOYSA-N 2-[[1-(2,6-diaminohexanoyl)pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NCCCCC(N)C(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O AFLBTVGQCQLOFJ-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- OGMADIBCHLQMIP-UHFFFAOYSA-N 2-aminoethanethiol;hydron;chloride Chemical compound Cl.NCCS OGMADIBCHLQMIP-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- WOVJYCOXFSGLMS-UHFFFAOYSA-N 4-(2-aminoethyl)-2-hydroxybenzoic acid Chemical compound NCCC1=CC=C(C(O)=O)C(O)=C1 WOVJYCOXFSGLMS-UHFFFAOYSA-N 0.000 description 1
- YJSMIMJDRSWLQQ-UHFFFAOYSA-N 4-(3-aminopropyl)-2-hydroxybenzoic acid Chemical compound NCCCC1=CC=C(C(O)=O)C(O)=C1 YJSMIMJDRSWLQQ-UHFFFAOYSA-N 0.000 description 1
- JQFZHHSQMKZLRU-IUCAKERBSA-N Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N JQFZHHSQMKZLRU-IUCAKERBSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 241001025137 Daltonia <moss> Species 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- MFBYPDKTAJXHNI-VKHMYHEASA-N Gly-Cys Chemical compound [NH3+]CC(=O)N[C@@H](CS)C([O-])=O MFBYPDKTAJXHNI-VKHMYHEASA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 125000002357 L-cystinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])SSC([H])([H])[C@@]([H])(C(O[H])=O)N([H])[H] 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- MSWZFWKMSRAUBD-UKFBFLRUSA-N alpha-D-glucosamine Chemical compound N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-UKFBFLRUSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- AEMOLEFTQBMNLQ-QIUUJYRFSA-N beta-D-glucuronic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-QIUUJYRFSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-aminopropionic acid Natural products NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 229940097265 cysteamine hydrochloride Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-N disulfuric acid Chemical compound OS(=O)(=O)OS(O)(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- WSYUEVRAMDSJKL-UHFFFAOYSA-N ethanolamine-o-sulfate Chemical compound NCCOS(O)(=O)=O WSYUEVRAMDSJKL-UHFFFAOYSA-N 0.000 description 1
- YVKSGVDJQXLXDV-BYPYZUCNSA-N ethyl (2r)-2-amino-3-sulfanylpropanoate Chemical compound CCOC(=O)[C@@H](N)CS YVKSGVDJQXLXDV-BYPYZUCNSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 1
- KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- VVNXEADCOVSAER-UHFFFAOYSA-N lithium sodium Chemical compound [Li].[Na] VVNXEADCOVSAER-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000008320 venous blood flow Effects 0.000 description 1
- GSQBIOQCECCMOQ-UHFFFAOYSA-N β-alanine ethyl ester Chemical compound CCOC(=O)CCN GSQBIOQCECCMOQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITBO920141A IT1260137B (it) | 1992-04-17 | 1992-04-17 | Glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2 dell'acido alfa-l-iduronico-2-0-solfato |
| ITBO920141 | 1992-04-17 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI931741A0 FI931741A0 (fi) | 1993-04-16 |
| FI931741A FI931741A (fi) | 1993-10-18 |
| FI106556B true FI106556B (fi) | 2001-02-28 |
Family
ID=11338176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI931741A FI106556B (fi) | 1992-04-17 | 1993-04-16 | Menetelmä puolisynteettisten glykosaminoglykaanien valmistamiseksi |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5430133A (el) |
| EP (1) | EP0565863B1 (el) |
| JP (1) | JP2702376B2 (el) |
| KR (1) | KR0171624B1 (el) |
| AT (1) | ATE154616T1 (el) |
| AU (1) | AU658498B2 (el) |
| CA (1) | CA2093147C (el) |
| DE (1) | DE69311619T2 (el) |
| DK (1) | DK0565863T3 (el) |
| ES (1) | ES2103992T3 (el) |
| FI (1) | FI106556B (el) |
| GR (1) | GR3024419T3 (el) |
| IL (1) | IL105112A (el) |
| IT (1) | IT1260137B (el) |
| NO (1) | NO305992B1 (el) |
| NZ (1) | NZ247196A (el) |
| TW (1) | TW239148B (el) |
| ZA (1) | ZA931798B (el) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5696100A (en) * | 1992-12-22 | 1997-12-09 | Glycomed Incorporated | Method for controlling O-desulfation of heparin and compositions produced thereby |
| IT1264101B1 (it) * | 1993-03-29 | 1996-09-10 | Alfa Wassermann Spa | Processo per la sintesi di glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2 |
| IT1264102B1 (it) * | 1993-03-29 | 1996-09-10 | Alfa Wassermann Spa | Processo per la sintesi di glicosaminoglicani semisintetici contenenti acido alfa-l-galatturonico sostituito con radicali |
| US5583121A (en) * | 1994-01-12 | 1996-12-10 | Michigan State University | Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes |
| US6127347A (en) * | 1994-01-12 | 2000-10-03 | Univ Michigan | Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes |
| US6255295B1 (en) | 1996-12-23 | 2001-07-03 | Nutramax Laboratories, Inc. | Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue |
| BR0012202A (pt) * | 1999-06-30 | 2002-04-02 | Hamilton Civic Hospitals Res | Composições de heparina de peso molecular médio (mmwh), método de tratamento de uma condição trombótica, método de prevenção da formação de um trombo, método de inibição da formação de trombos, composição farmacêutica, método de tratamento de trombose venosa profunda, método de prevenção de embolia pulmonar, método de preparação e usos de uma composição de mmwh |
| US7259152B2 (en) | 2000-06-07 | 2007-08-21 | Alfa Wasserman, Inc. | Methods and compositions using sulodexide for the treatment of diabetic nephropathy |
| AU2001291549A1 (en) * | 2000-09-08 | 2002-03-22 | Hamilton Civic Hospitals Research Development Inc. | Antithrombotic compositions |
| AU2003225724A1 (en) * | 2002-03-11 | 2003-09-29 | Momenta Pharmaceuticals, Inc. | Analysis of sulfated polysaccharides |
| GB0216861D0 (en) * | 2002-07-19 | 2002-08-28 | Univ Birmingham | Saccharide libraries |
| US9139876B1 (en) | 2007-05-03 | 2015-09-22 | Momenta Pharmacueticals, Inc. | Method of analyzing a preparation of a low molecular weight heparin |
| WO2009014715A2 (en) * | 2007-07-23 | 2009-01-29 | The University Of North Carolina At Chapel Hill | Enzymatic synthesis of sulfated polysaccharides without iduronic acid residues |
| ES2817779T3 (es) * | 2010-01-19 | 2021-04-08 | Momenta Pharmaceuticals Inc | Evaluación de preparaciones de heparina |
| KR101794877B1 (ko) * | 2010-09-14 | 2017-11-07 | 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 | 고순도 헤파린 및 그 제조방법 |
| US11203772B2 (en) | 2010-12-23 | 2021-12-21 | The University Of North Carolina At Chapel Hill | Chemoenzymatic synthesis of structurally homogeneous ultra-low molecular weight heparins |
| US9068957B2 (en) | 2011-02-21 | 2015-06-30 | Momenta Pharmaceuticals, Inc. | Evaluating heparin preparations |
| DE102011077393A1 (de) * | 2011-06-10 | 2012-12-13 | Johannes Reinmüller | Antiinfektives Mittel |
| WO2014204929A2 (en) | 2013-06-17 | 2014-12-24 | The University Of North Carolina At Chapel Hill | Reversible heparin molecules and methods of making and using the same |
| WO2018165656A1 (en) | 2017-03-10 | 2018-09-13 | The University Of North Carolina At Chapel Hill | Short-acting heparin-based anticoagulant compounds and methods |
| US11993627B2 (en) | 2017-07-03 | 2024-05-28 | The University Of North Carolina At Chapel Hill | Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides |
| CN111601603A (zh) | 2017-11-03 | 2020-08-28 | 北卡罗来纳大学查珀尔希尔分校 | 具有抗炎活性的硫酸化寡糖 |
| CN112437667B (zh) | 2018-06-20 | 2024-05-28 | 北卡罗来纳大学查珀尔希尔分校 | 细胞保护方法和组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4987223A (en) * | 1981-12-23 | 1991-01-22 | Choay S.A. | Derivatives of the uronic acid |
| IT1234508B (it) * | 1988-06-10 | 1992-05-19 | Alfa Wassermann Spa | Derivati eparinici e procedimento per la loro preparazione |
| DE3821271A1 (de) * | 1988-06-23 | 1989-12-28 | Solco Basel Ag | Derivatisiertes heparin, verfahren zu dessen herstellung und arzneimittel, welches dieses enthaelt |
| IT1234826B (it) * | 1989-01-30 | 1992-05-29 | Alfa Wassermann Spa | Derivati eparinici e procedimento per la loro preparazione |
| US5464942A (en) * | 1990-07-24 | 1995-11-07 | Seikagaku Kogyo Kabushiki Kaisha | Phospholipid- or lipid-linked glycosaminoglycan and process for producing the same |
| US5200523A (en) * | 1990-10-10 | 1993-04-06 | Monsanto Company | Synthesis of nojirimycin derivatives |
| IT1260136B (it) * | 1992-04-17 | 1996-03-28 | Alfa Wassermann Spa | Glicosaminoglicani semisintetici contenenti acido alfa-l-galatturonicosostituito con radicali nucleofili in posizione 3 |
-
1992
- 1992-04-17 IT ITBO920141A patent/IT1260137B/it active IP Right Grant
-
1993
- 1993-03-10 DK DK93103848.3T patent/DK0565863T3/da active
- 1993-03-10 DE DE69311619T patent/DE69311619T2/de not_active Expired - Fee Related
- 1993-03-10 ES ES93103848T patent/ES2103992T3/es not_active Expired - Lifetime
- 1993-03-10 AT AT93103848T patent/ATE154616T1/de not_active IP Right Cessation
- 1993-03-10 EP EP93103848A patent/EP0565863B1/en not_active Expired - Lifetime
- 1993-03-12 ZA ZA931798A patent/ZA931798B/xx unknown
- 1993-03-18 NZ NZ247196A patent/NZ247196A/en unknown
- 1993-03-19 TW TW082102014A patent/TW239148B/zh active
- 1993-03-19 IL IL10511293A patent/IL105112A/xx not_active IP Right Cessation
- 1993-03-30 NO NO931184A patent/NO305992B1/no not_active IP Right Cessation
- 1993-04-01 CA CA002093147A patent/CA2093147C/en not_active Expired - Fee Related
- 1993-04-13 US US08/046,248 patent/US5430133A/en not_active Expired - Lifetime
- 1993-04-13 AU AU36895/93A patent/AU658498B2/en not_active Ceased
- 1993-04-16 JP JP5089976A patent/JP2702376B2/ja not_active Expired - Fee Related
- 1993-04-16 FI FI931741A patent/FI106556B/fi not_active IP Right Cessation
- 1993-04-17 KR KR1019930006473A patent/KR0171624B1/ko not_active IP Right Cessation
-
1997
- 1997-08-13 GR GR970402062T patent/GR3024419T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ITBO920141A1 (it) | 1993-10-17 |
| CA2093147C (en) | 1999-01-26 |
| FI931741A (fi) | 1993-10-18 |
| KR930021650A (ko) | 1993-11-22 |
| TW239148B (el) | 1995-01-21 |
| AU658498B2 (en) | 1995-04-13 |
| JP2702376B2 (ja) | 1998-01-21 |
| DK0565863T3 (da) | 1997-12-15 |
| ES2103992T3 (es) | 1997-10-01 |
| ZA931798B (en) | 1993-11-22 |
| IT1260137B (it) | 1996-03-28 |
| US5430133A (en) | 1995-07-04 |
| JPH0616703A (ja) | 1994-01-25 |
| KR0171624B1 (ko) | 1999-02-01 |
| EP0565863B1 (en) | 1997-06-18 |
| NO305992B1 (no) | 1999-08-30 |
| AU3689593A (en) | 1993-10-21 |
| GR3024419T3 (en) | 1997-11-28 |
| ATE154616T1 (de) | 1997-07-15 |
| EP0565863A3 (en) | 1993-11-10 |
| DE69311619D1 (de) | 1997-07-24 |
| NZ247196A (en) | 1995-02-24 |
| NO931184D0 (no) | 1993-03-30 |
| DE69311619T2 (de) | 1997-12-11 |
| IL105112A (en) | 1997-01-10 |
| EP0565863A2 (en) | 1993-10-20 |
| NO931184L (no) | 1993-10-18 |
| IL105112A0 (en) | 1993-07-08 |
| CA2093147A1 (en) | 1993-10-18 |
| ITBO920141A0 (it) | 1992-04-17 |
| FI931741A0 (fi) | 1993-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI106556B (fi) | Menetelmä puolisynteettisten glykosaminoglykaanien valmistamiseksi | |
| FI106555B (fi) | Menetelmä puolisynteettisten glykosaminoglykaanien valmistamiseksi | |
| EP2103631B1 (en) | Mercapto-group modified macromolecule derivative and cross-linked material | |
| Coneski et al. | Synthesis of nitric oxide-releasing polyurethanes with S-nitrosothiol-containing hard and soft segments | |
| FI101541B (fi) | Menetelmä trisakkaridiyksikön sisältävien terapeuttisesti käyttökelpoi sten hiilihydraattijohdannaisten valmistamiseksi | |
| KR20000075663A (ko) | 높은 항혈전용해 활성을 갖는 글리코스아미노글리칸 | |
| US5110918A (en) | Process for preparing EDTA-free heparins, heparin fractions and fragments | |
| FI105100B (fi) | Menetelmä puolisynteettisten glykosaminoglykaanien valmistamiseksi, jotka sisältävät nukleofiilisillä radikaaleilla 3-asemassa substituoitua alfa-L-galakturonihappoa | |
| AU664939B2 (en) | Process for the synthesis of semi-synthetic glycosaminoglycans with heparin or heparan structure modified in position 2 of the alpha-L-iduronic-2-O-sulfate acid | |
| KR920003692B1 (ko) | 다당류의 해중합 및 황산염화 방법 | |
| CZ431699A3 (cs) | Směsi oligosacharidů s antitrombotickou účinností | |
| JPH0643446B2 (ja) | キトサン６−スルフエ−トおよびその製法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MA | Patent expired |